Study confirms validity of data from internet-recruited patients
Quintiles' latest study could pave the way for more direct-to-patient studies using patient-reported outcomes combined with medical record data.
A study has confirmed the reliability of data collected via patients who are recruited over the internet for the purpose of observational studies.
The internet provides a useful source of patients, who can be recruited, screened and enrolled online without physical contact.
Now, the latest study from Quintiles' Digital Patient Unit (DPU) has confirmed that patient-reported outcomes collected from participants recruited in this way are indeed reliable.
This means trial leaders can perform observational research that combines patient-reported outcomes and medical record data without worrying about the reliability of their results.
Elisa Cascade, vice-president of Quintiles' DPU and co-author of the study in the Journal of Medical Internet Research, said the results were "positive".
She revealed: "This pilot validates the use of patient-reported outcomes when collected in this manner. It is a foundational step toward broader use of this design in collecting real-world, observational data."
Dr Rich Gliklich, president of Quintiles Outcomes, added that direct-to-patient studies will become "increasingly important", given the widespread demand for rapid data collection.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.